This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

18 Mar 2022

KKR-backed Biosynth Carbosynth acquires Vivitide

KKR closes its previously-announced acquisition of Biosynth Carbosynth and announces Biosynth's acquisition of vivitide. 

Investment firm KKR has closed its acquisition of UK life sciences company Biosynth Carbosynth, and announced Biosynth's acquisition of vivitide, which provides custom peptides and antibodies for the biotech industry.

Previous vivitide owner Ampersand Capital Partners will become a minority stakeholder in the combined entity. KKR and Ampersand say they plan to accelerate the company’s geographic expansion, broaden its capabilities and expand its product portfolio. 

KKR utilized a $4 billion strategic growth fund focused on high-growth health care companies to invest in Biosynth Carbosynth. Company leadership believe the move will position Biosynth Carbosynth as a premium global platform serving high-growth end markets in the life sciences. 

Speaking on the acquisition, Biosynth Carbosynth CEO Dr. Urs Spitz said the deal marks an “important milestone” in the company’s journey, adding that Biosynth will “benefit greatly from vivitide’s strong U.S. presence, complementary portfolio of products and services, and entrepreneurial culture.” 

Vivitide CEO Dr. Martina Diekmann said she was proud to join forces with Biosynth, noting that the acquisition will allow an acceleration of growth and expanded product offering.  


Related News